These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 24632953

  • 1. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist.
    Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Hatano M, Yao A, Komuro I.
    Int Heart J; 2014; 55(2):131-7. PubMed ID: 24632953
    [Abstract] [Full Text] [Related]

  • 2. Hypernatremia induced by low-dose Tolvaptan in a Patient with refractory heart failure: A case report.
    Li T, Li GS.
    Medicine (Baltimore); 2019 Jul; 98(27):e16229. PubMed ID: 31277136
    [Abstract] [Full Text] [Related]

  • 3. Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure.
    Imamura T, Kinugawa K, Komuro I.
    Int Heart J; 2016 Jul; 57(1):41-6. PubMed ID: 26742881
    [Abstract] [Full Text] [Related]

  • 4. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ, Ahmad F, Blais JD, Chiodo J, Zhou W, Glaser LA, Czerwiec FS.
    Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
    [Abstract] [Full Text] [Related]

  • 5. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.
    Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R.
    Circ J; 2013 Apr; 77(2):397-404. PubMed ID: 23131721
    [Abstract] [Full Text] [Related]

  • 6. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M, Sunagawa O, Kinugawa K.
    Int Heart J; 2018 Apr; 59(1):87-93. PubMed ID: 29375117
    [Abstract] [Full Text] [Related]

  • 7. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.
    Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, Yao A, Komuro I.
    Circ J; 2014 Apr; 78(9):2240-9. PubMed ID: 24954239
    [Abstract] [Full Text] [Related]

  • 8. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.
    Cyr PL, Slawsky KA, Olchanski N, Krasa HB, Goss TF, Zimmer C, Hauptman PJ.
    Am J Health Syst Pharm; 2011 Feb 15; 68(4):328-33. PubMed ID: 21289328
    [Abstract] [Full Text] [Related]

  • 9. Tolvaptan can improve clinical course in responders.
    Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Hatano M, Yao A, Komuro I.
    Int Heart J; 2013 Feb 15; 54(6):377-81. PubMed ID: 24309447
    [Abstract] [Full Text] [Related]

  • 10. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH, Bohm NM, Nemecek BD, Crawford R, Kelley D, Bhasin B, Nietert PJ, Velez JCQ.
    Am J Kidney Dis; 2018 Jun 15; 71(6):772-782. PubMed ID: 29478867
    [Abstract] [Full Text] [Related]

  • 11. Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial.
    Shanmugam E, Doss CR, George M, Jena A, Rajaram M, Ramaraj B, Anjaneyan K, Kanagesh B.
    Indian Heart J; 2016 Apr 15; 68 Suppl 1(Suppl 1):S15-21. PubMed ID: 27056648
    [Abstract] [Full Text] [Related]

  • 12. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N, Kida K, Inomata T, Sato N, Izumi T, Akashi YJ, Shibagaki Y.
    Am J Nephrol; 2017 Apr 15; 46(5):417-426. PubMed ID: 29130954
    [Abstract] [Full Text] [Related]

  • 13. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.
    Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K.
    Intern Med; 2017 Nov 15; 56(22):2993-3001. PubMed ID: 28943585
    [Abstract] [Full Text] [Related]

  • 14. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP, DeVita MV, Michelis MF.
    Int Urol Nephrol; 2012 Jun 15; 44(3):865-71. PubMed ID: 21607553
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
    Der-Nigoghossian C, Lesch C, Berger K.
    Pharmacotherapy; 2017 May 15; 37(5):528-534. PubMed ID: 28295447
    [Abstract] [Full Text] [Related]

  • 16. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study.
    Minami S, Hamano T, Iwatani H, Mizui M, Kimura Y, Isaka Y.
    Clin Exp Nephrol; 2018 Jun 15; 22(3):550-561. PubMed ID: 29052786
    [Abstract] [Full Text] [Related]

  • 17. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, Liu ZM, Ma JH, Zhang ZW, Gu F.
    J Clin Pharmacol; 2014 Dec 15; 54(12):1362-7. PubMed ID: 24906029
    [Abstract] [Full Text] [Related]

  • 18. Combination of Urinary Sodium/Creatinine Ratio and Plasma Brain Natriuretic Peptide Level Predicts Successful Tolvaptan Therapy in Patients With Heart Failure and Volume Overload.
    Sato Y, Dohi K, Watanabe K, Tanimura M, Takeuchi T, Sugiura E, Sugimoto T, Kumagai N, Ogura T, Nakamori S, Fujimoto N, Yamada N, Ito M.
    Int Heart J; 2016 Dec 15; 57(2):211-9. PubMed ID: 26973271
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome.
    Saimiya M, Kaku Y, Nishimura M.
    CEN Case Rep; 2021 Nov 15; 10(4):523-526. PubMed ID: 33904139
    [Abstract] [Full Text] [Related]

  • 20. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
    Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H.
    Intern Med; 2018 Sep 01; 57(17):2451-2458. PubMed ID: 29607963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.